H.C. Wainwright lowered the firm’s price target on Santhera Pharmaceuticals to CHF 25 from CHF 30 and keeps a Buy rating on the shares. The company completed multiple transactions completed, providing an operational runway through to potential cash flow breakeven, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.